Phase I/II dose-escalation trial of RGX-111 for the treatment of mucopolysaccharidosis type I
Phase of Trial: Phase I/II
Latest Information Update: 06 Jan 2017
At a glance
- Drugs RGX 111 (Primary)
- Indications Mucopolysaccharidosis I
- Focus Adverse reactions; First in man
- 06 Jan 2017 According to a REGENXBIO media release, the company expects to begin enrollment in the study in the second half of 2017.
- 05 Jul 2016 According to Regenxbio media release, company expects to submit an IND of RGX-111 in the U.S. and Canada in the first half of 2017.
- 07 Jan 2016 According to a media release, REGENXBIO intends to file IND application with the FDA in the first half of 2016 and plans to initiate this trial in the second half of 2016.